---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-106246"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:31:44.656711+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aptevo Q2 net loss $6.2M; mipletamig 85% remission in AML; pipeline expands with APVO455

## Summary
- Net loss $6.2M for Q2 2025; cash $9.4M as of June 30, 2025.
- Raised $15.9M in Q2; extended cash runway into late Q4 2025; secured up to $25M equity line.
- Introduced APVO455, a Nectin-4 x CD3 bispecific for bladder, breast, NSCLC, head & neck cancers.
- Mipletamig achieved 85% remission rate (11/13) in frontline AML; no CRS reported.
- Shares outstanding grew to 3,224,156 vs 72,922 at Dec 31, 2024 due to equity raises.

## SEC filing metadata
- accession: 0000950170-25-106246
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000095017025106246/0000950170-25-106246-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000095017025106246/apvo-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-106246
- JSON: https://secwatch.observer/filing/0000950170-25-106246.json
- Plain text: https://secwatch.observer/filing/0000950170-25-106246.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.